A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Inclusion Criteria:

Participants are eligible to be included in the study only if all of the following criteria apply:

• Stable moderate to severe plaque psoriasis for at least 6 months

• Baseline score of PASI >= 12, involvement of >= 10% BSA, and sPGA >= 3 at screeningand at baseline

• Candidate for phototherapy or systemic therapy

• Previous failure, inadequate response, intolerance, or contraindication to at least 1 conventional anti-psoriatic systemic therapy

• Female participants should have negative serum pregnancy test during screening and anegative urine pregnancy test at baseline

• No known history of latent or active tuberculosis (TB), and has a negative test forTB during screening (with negative purified protein derivative (PPD), and NegativeQuantiferon®/T-spot test)

• Participants with a positive purified protein derivative and a history of BacillusCalmette-Guérin (BCG) vaccination are allowed with a negative Quantiferon®/T-spot®

• Participants with a positive PPD test (without history of BCG vaccination) orparticipants with a positive or indeterminate Quantiferon®/T-spot test are allowedif they have all of the following:

• No symptoms per TB worksheet provided by the sponsor

• Documented history of adequate prophylaxis initiation prior to receivinginvestigational product (IP) in accordance with local recommendations

• No known exposure to a case of active TB after most recent prophylaxis

• No evidence of active TB on chest radiograph within 3 months prior to the firstdose of IP

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

• Skin disease related conditions such as, Erythrodermic psoriasis (PsO), pustularPsO, guttate PsO, medication induced PsO, or other skin conditions at the time ofthe screening visit (eg, eczema) that would interfere with evaluations of the effectof IP on PsO

• Participant has an active infection, recurrent or chronic infections, seriousinfection or history of infections

• Known history of human immunodeficiency virus

• Hepatitis B surface antigen or hepatitis C virus antibody positivity at screening

• Uncontrolled, clinically significant systemic disease such as uncontrolled diabetesmellitus, cardiovascular disease, renal disease, liver disease, or hypertension

• Moderate to severe heart failure (New York Heart Associate class III/IV)

• Known hypersensitivity to the IP or to any of the excipients

• Any abnormal laboratory parameters at screening, as defined in protocol

• Previous treatment with any agent specifically targeting interleukin (IL)-12 orIL-23

• Received biologic treatment for psoriasis within the previous month or 5 drughalf-lives prior to randomization

• Received non-biologic systemic psoriasis therapy within 4 weeks prior torandomization

• Received Ultra-violet A (UVA) phototherapy (with or without psoralen) or excimerlaser within 4 weeks prior to randomization, or ultra-violet B (UVB) phototherapywithin 2 weeks prior to randomization

• Received topical psoriasis treatment within 2 weeks prior to randomization (exception: upper mid-strength to least potent [class III to VII] topical steroidspermitted on the palms, soles, face, and intertriginous areas; bland emollients)

• Received live viral or live bacterial vaccination within 2 weeks prior torandomization

• Received BCG vaccination within 1 year prior to randomization

• Other investigational procedures within 4 weeks prior to randomization and duringthe study

• Participants not agreeing to follow protocol defined contraceptives procedures

• Participants likely not to be available to complete all protocol-required studyvisits or procedures, and/or to comply with all required study procedures